Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody 2021

Known as: concizumab, mAb 2021 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Results from the main parts (24 weeks) of two concizumab phase 2 trials are presented: explorer4 (NCT03196284) in hemophilia A… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2019
2019
Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor… Expand
Review
2018
Review
2018
Replacement therapy with missing factor (F) VIII or IX in haemophilia patients for bleed management and preventative treatment or… Expand
  • figure 1
  • table 1
2018
2018
Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic… Expand
2017
2017
Concizumab, a humanized monoclonal antibody against tissue factor pathway inhibitor (TFPI), is being developed as a… Expand
2016
2016
The development of inhibitors to factor VIII (FVIII) or factor IX (FIX) remains a major treatment complication encountered in the… Expand
Highly Cited
2015
Highly Cited
2015
Prophylaxis with either intravenous (i.v.) factor VIII (FVIII) or FIX is the gold standard of care for patients with severe… Expand
2014
2014
INTRODUCTION Concizumab (mAb 2021) is a monoclonal IgG4 antibody (mAb) that binds to the Kunitz-type protease inhibitor (KPI) 2… Expand
2014
2014
INTRODUCTION A humanised monoclonal antibody, concizumab, that binds with high affinity to the Kunitz-type protease inhibitor… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4